Recombinant full-length human protein was used as the immunogen for the p21 antibody. This antibody is not suitable for testing mouse and rat samples.
p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).
Klonalität:
Monoclonal
Konzentration:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Reinheit:
Protein G affinity chromatography
Formulierung:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Target-Kategorie:
p21
Antibody Type:
Primary Antibody
Application Verdünnung:
Immunofluorescence: 1-2ug/ml,Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 2-4ug/ml for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)
Anwendungsbeschreibung:
Optimal dilution of the p21 antibody to be determined by the researcher.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
IHC testing of human lung squamous c
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
